Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.71 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RXRA | P19793 | 2/20 | 0.50 |
| ▸ | RXRB | P28702 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 6/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12894973 | 0.83 | BCL2 (1.00) | BCL2PTGS2RXRARXRBAOC3 | |
| SCHEMBL13099462 | 0.83 | BCL2 (0.76) | BCL2PTGS2SMN1; SMN2MAPTRXRA | |
| SCHEMBL13675283 | 0.83 | ALDH1A1 (0.55) | BCL2SMN1; SMN2L3MBTL1MAPTRXRA | |
| SCHEMBL6640696 | 0.82 | BCL2 (0.73) | BCL2PTGS2SMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL6951663 | 0.82 | BCL2 (0.68) | BCL2PTGS2SMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL13060799 | 0.81 | HPGD (0.69) | BCL2PTGS2SMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL924897 | 0.81 | CYP4F2 (0.49) | BCL2PTGS2SMN1; SMN2MAPT | |
| SCHEMBL13818521 | 0.81 | BCL2 (0.62) | BCL2PTGS2RXRARXRBAOC3 | |
| SCHEMBL17740358 | 0.81 | BCL2 (0.71) | BCL2PTGS2MAPTRXRARXRB | |
| SCHEMBL13060851 | 0.79 | BCL2 (0.69) | BCL2PTGS2MAPTRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270381-A1 | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2009-10-29 | — | — | US | disclosed |
| WO-2009077186-A1 | NONSTEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESLLSCHAFT (DE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270381-A1 | Non-steroidal progesterone receptor modulators | PGR, PGRMC1, PGRMC2 | BCL2 2800/4885PTGS2 48/4885SMN1; SMN2 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.